1 to 10 of 39
Sort by

Library Entry
An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors

To evaluate whether administration of the oral DNA hypomethylating agent CC-486 enhances the poor response rate of immunologically ‘cold’ solid tumors to immune checkpoint inhibitor durvalumab, PD-L1/PD-1 inhibitor naïve patients with advanced microsatellite stable colorectal cancer, platinum...

Library Entry
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses

Strategies to improve activity of immune checkpoint inhibitors are needed. The authors hypothesized enhanced DNA damage by olaparib, a PARP inhibitor, and reduced VEGF signaling by cediranib, a VEGFR1–3 inhibitor, would complement anti-tumor activity of durvalumab, a PD-L1 inhibitor, and the 3...

Library Entry
Webinar: Stage III Non-small Cell Lung Cancer and Immunotherapy

LUNGevity sat down with Patrick Forde, MD (MB, BCH), Associate Professor of Oncology at the Johns Hopkins School of Medicine, to discuss the results of the PACIFIC trial and what it means for the lung cancer survivor community. Dr. Forde is an expert on immunotherapies for lung cancer and has...

Library Entry
Treatment Options for Lung Adenocarcinoma (from LUNGevity)

There are numerous treatment options available to people affected by lung adenocarcinoma, and doctors are working hard to develop and improve these treatments. This website from LUNGevity can help you: Learn about lung adenocarcinoma Understand the treatment options available for...

Library Entry
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors

PD-L1 immunohistochemistry (IHC) has been traditionally used for predicting clinical responses to immune checkpoint inhibitors (ICIs). However, there are at least 4 different assays and antibodies used for PD-L1 IHC, each developed with a different ICI. The authors set to test if next generation...